Inclusion/Exclusion Criteria. Otherwise healthy ambulatory postmenopausal women who participated in, and who completed 18 months of treatment with either blinded BA058 Injection 80 µg or blinded Placebo in Study BA058-05-003, are scheduled to complete or have completed the End-of-Treatment visit (Visit 9 in Study BA058-05-003), and who have provided a new written informed consent for the Extension Study, are eligible for enrollment into this study. Participants must be no more than 40 days from Visit 9 in Study BA058-05-003 to be eligible for this study. The physical examinations and clinical laboratory measurements from the End-of-Treatment visit from Protocol BA058-05-003 (Visit 9) of the BA058-
Inclusion/Exclusion Criteria. Given the overall paucity of research on HD, we aimed to include as many studies as possible. As such, any twin study reporting on heritability estimates on the hoarding phenotype regardless of study design (e.g. volunteer, population-based or register-based) was considered eligible for inclusion in the current review. Records were excluded if they were not a twin study (e.g. family, molecular genetic, animal studies) or did not report heritability estimates for the phenotype of interest. Twin studies on the same samples were included as long as the instrument utilised differed between studies (e.g. Xxxxxxxxx et al., 2009 and Xxxxxxxxx et al., 2011); on the other hand, when several publications reported on the same twin sample and measures, we opted to include the largest one reporting on univariate twin analyses on hoarding symptoms.
Inclusion/Exclusion Criteria. All inclusion and exclusion criteria will be reviewed and documented by the investigator or qualified designee to ensure that the patient qualifies for the trial.
Inclusion/Exclusion Criteria. The Registry Protocol has specifically defined inclusion and exclusion criteria for patients who may be enrolled in the follow-up. The Investigator shall fully comply with the requirements indicated in the Study Protocol. (f) Reports The Investigator shall report and follow all complications whether they are or are not related to the device, surgical procedure, postoperative Pokud mají být později do zkoušejícího týmu zařazeny další osoby, zkoušející bude mít povinnost nahlásit společnosti Stryker tyto osoby dříve než zahájí činnost, a získat písemný souhlas společnosti Stryker, aby tyto osoby mohly být zaneseny do Přílohy A této smlouvy. Bez takové dodatečné dohody nesmí zkoušející svěřit dalším spolupracujícím osobám výkon povinností vyplývajících pro zkoušejícího z této smlouvy. Zkoušející zajistí, že zkoušející tým bude dodržovat veškeré povinnosti vyplývající z této smlouvy, především zajištění důvěrnosti, ochrany osobních údajů a utajení výsledků práce, vynálezů a zjištění, a to i po ukončení této smlouvy. (d) Neúčast pacientů na následném sledování Pro úspěch registru je zásadní zajistit následné sledování všech pacientů v souladu s protokolem registru. Zkoušející předem upozorní pacienty, které do registru zařadí, na to, co se od nich očekává, a vysvětlí, jak je důležité, aby se dostavili na následné návštěvy po celou dobu trvání registru. Společnost Stryker poskytne informační brožuru pro pacienty, kterou si mají přečíst před podepsáním informovaného souhlasu. (e) Kritéria pro zařazení do registru Protokol registru definuje specifická kritéria pro zařazení/nezařazení pacientů do následného sledování. Zkoušející bude plně dodržovat požadavky uvedené v protokolu hodnocení. (f) Hlášení Zkoušející bude hlásit a sledovat všechny komplikace, ať už budou nebo nebudou souviset se zařízením, chirurgickým výkonem, pooperační péčí nebo příčinami. Zkoušející poskytne plnou pomoc s tímto aspektem registru.
Inclusion/Exclusion Criteria. All patients admitted to the AVAMC acute care medical facility from October 1st, 2007, through February 1st 2008 (4 months), were eligible to be included in the study population. All patients with positive admission nasal MRSA surveillance results were included in the study. A random sample of patients from the same time period with negative admission nasal MRSA surveillance results was also included. Patients without admission nasal colonization results were excluded. Patients sent to the AVAMC for a surgical procedure with no prior or subsequent follow-up within the AVAMC system were also excluded. The inpatient psychiatric department does not perform MRSA nasal surveillance routinely and thus were excluded from the study population.
Inclusion/Exclusion Criteria. For this analysis, we used data from ever-married women, village, and health sub-center surveys. For our two outcomes, (IFA receipt and IFA consumption), we constructed two final samples. We included women in our data analysis that had a live birth in the time period surveyed (from January 1, 2004 to 2007-08), lived in a primary sampling unit (PSU) covered by only one HSC, and had complete data for the outcome of interest and covariates. Due to these inclusion criteria, all women who did not attend ANC (and thus were not asked about IFA receipt or consumption) and those who lived in urban residences (and were not covered by an HSC) were excluded. Women with incomplete or implausible data were also excluded. In our IFA consumption model, women who did not receive IFA were not asked about consumption and therefore excluded from that model (See Figure 4.1a). We also excluded HSCs that did not cover a primary sampling unit (PSU) with an ever- married woman in our model, that covered more than one PSU, or that had missing data. In rural populations, PSUs were defined as census villages or communities24. For the IFA receipt outcome, we included 1,012 HSCs and for the IFA consumption second outcome, 890 HSCs (See Figure 4.1b). There were some differences between the total sample and our analysis samples. Women included in our models were older, more educated, of higher birth order, and less likely to be married before the age of 18 or be of a scheduled caste or tribe. Women included in our second model (IFA consumption), were more likely to have initiated ANC earlier, have more frequent ANC visits, and experienced more ANC practice and counseling. HSCs that were excluded were more likely to be in need of repair. Dependent Variables We constructed two primary outcomes for this analysis. Both outcomes were dichotomous variables regarding IFA supplements provided during ANC as routine standard of care through the government health system. Government guidelines require one dose of IFA to be 100mg elemental iron (ferrous sulphate18) and 500 mcg folic acid from tablets or syrup26. The first outcome was defined as receipt of any iron and folic acid supplements during the last pregnancy. Interviewers asked women who reported having attended ANC how many IFA tablets or bottles they received during their last pregnancy. This included any quantity of IFA tables or IFA syrup. Those who answered any number greater than zero were classified as having received IFA 25. Women who...
Inclusion/Exclusion Criteria. Otherwise healthy ambulatory postmenopausal women who participated in, and who completed 18 months of treatment with either blinded Abaloparatide-SC or blinded Placebo in Study BA058-05-003, are scheduled to complete or have completed the End-of-Treatment visit (Visit 9 in Study BA058-05-003), and who have provided a new written informed consent for the Extension Study, are eligible for enrollment into this study. Participants must be no more than 40 days from Visit 9 in Study BA058-05-003 to be eligible for this study. The physical examinations and clinical laboratory Radius Health, Inc. Confidential measurements from the End-of-Treatment visit from Protocol BA058-05-003 (Visit 9) of the BA058-05-003 study will provide baseline data for this Extension Study. In addition, the subjects must, in the opinion of the Investigator, be appropriate candidates for treatment with alendronate. Subjects will not be enrolled if they experienced a treatment-related SAE as assessed by the Investigator, or if they were withdrawn from Study BA058-05-003 for any reason. Specific inclusion and exclusion criteria are described in Section 4.1 and Section 4.2, respectively.
Inclusion/Exclusion Criteria. Otherwise healthy ambulatory postmenopausal women who participated in, and who completed 18 months of treatment with either blinded Abaloparatide-SC or blinded Placebo in Study BA058-05-003, are scheduled to complete or have completed the End-of-Treatment visit (Visit 9 in Study BA058-05-003), and who have provided a new written informed consent for the Extension Study, are eligible for enrollment into this study. Participants must be no more than 40 days from Visit 9 in Study BA058-05-003 to be eligible for this study. The physical examinations and clinical laboratory measurements from the End-of-Treatment visit from Protocol BA058-05-003 (Visit 9) of the BA058-05-003 study will provide baseline data for this Extension Study. In addition, the subjects must, in the opinion of the Investigator, be appropriate candidates for treatment with alendronate. Subjects will not be enrolled if they experienced a treatment-related SAE as assessed by the Investigator, or if they were withdrawn from Study BA058-05-003 for any reason. Specific inclusion and exclusion criteria are described in Section 4.1 and Section 4.2, respectively.
Inclusion/Exclusion Criteria. All individuals in each household were surveyed regardless of MDA eligibility. For this study however, only individuals eligible for MDA were included. Individuals who were reportedly ineligible (too young, pregnant/lactating, or severely ill) at the time of MDA were excluded from the analysis. Observations for children under five years of age were also excluded for ALB, IVM and PZQ drug types, and children less than six months of age were excluded for ZITH. While children over two years were eligible for ALB, children under five years were ineligible for IVM, and the two drugs were administered in combination during the LF MDAs (children under five were likely skipped over for both drug types). Additional exclusions included those missing a coverage response, and observations collected using EPI and LQAS survey methods in Uganda. Data collected using the EPI and LQAS survey methods in Uganda were excluded to control for possible duplications due to surveys being conducted in the same district.
